These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7478571)

  • 1. Tyrosine phosphorylation of murine Crkl.
    de Jong R; Haataja L; Voncken JW; Heisterkamp N; Groffen J
    Oncogene; 1995 Oct; 11(8):1469-74. PubMed ID: 7478571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site.
    de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
    Oncogene; 1997 Feb; 14(5):507-13. PubMed ID: 9053848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of Bcr/Abl with C3G, an exchange factor for the small GTPase Rap1, through the adapter protein Crkl.
    Cho YJ; Hemmeryckx B; Groffen J; Heisterkamp N
    Biochem Biophys Res Commun; 2005 Aug; 333(4):1276-83. PubMed ID: 15982636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3G is tyrosine-phosphorylated after integrin-mediated cell adhesion in normal but not in Bcr/Abl expressing cells.
    de Jong R; van Wijk A; Heisterkamp N; Groffen J
    Oncogene; 1998 Nov; 17(21):2805-10. PubMed ID: 9840945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular interactions of CRKL, and SH2-SH3 adaptor protein.
    ten Hoeve J; Kaartinen V; Fioretos T; Haataja L; Voncken JW; Heisterkamp N; Groffen J
    Cancer Res; 1994 May; 54(10):2563-7. PubMed ID: 8168080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells.
    Tari AM; Arlinghaus R; Lopez-Berestein G
    Biochem Biophys Res Commun; 1997 Jun; 235(2):383-8. PubMed ID: 9199202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.
    Nichols GL; Raines MA; Vera JC; Lacomis L; Tempst P; Golde DW
    Blood; 1994 Nov; 84(9):2912-8. PubMed ID: 7524758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
    Salgia R; Pisick E; Sattler M; Li JL; Uemura N; Wong WK; Burky SA; Hirai H; Chen LB; Griffin JD
    J Biol Chem; 1996 Oct; 271(41):25198-203. PubMed ID: 8810278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.
    de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
    J Biol Chem; 1995 Sep; 270(37):21468-71. PubMed ID: 7545163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
    Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N
    Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl.
    de Jong R; van Wijk A; Haataja L; Heisterkamp N; Groffen J
    J Biol Chem; 1997 Dec; 272(51):32649-55. PubMed ID: 9405482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
    Gutiérrez-Berzal J; Castellano E; Martín-Encabo S; Gutiérrez-Cianca N; Hernández JM; Santos E; Guerrero C
    Exp Cell Res; 2006 Apr; 312(6):938-48. PubMed ID: 16443220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells.
    Salgia R; Uemura N; Okuda K; Li JL; Pisick E; Sattler M; de Jong R; Druker B; Heisterkamp N; Chen LB
    J Biol Chem; 1995 Dec; 270(49):29145-50. PubMed ID: 7493940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
    Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
    Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
    Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
    Uemura N; Salgia R; Li JL; Pisick E; Sattler M; Griffin JD
    Leukemia; 1997 Mar; 11(3):376-85. PubMed ID: 9067577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
    Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
    Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase.
    Oda T; Kujovich J; Reis M; Newman B; Druker BJ
    Oncogene; 1997 Sep; 15(11):1255-62. PubMed ID: 9315092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells.
    Sattler M; Salgia R
    Leukemia; 1998 May; 12(5):637-44. PubMed ID: 9593259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.
    ten Hoeve J; Arlinghaus RB; Guo JQ; Heisterkamp N; Groffen J
    Blood; 1994 Sep; 84(6):1731-6. PubMed ID: 7521685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.